Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

TRDA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Entrada Therapeutics, Inc.NASDAQ: TRDA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $4.74M fell 6.7% year over year, behind the -0.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 8.9% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.

Context

  • Stock-based compensation amounted to 77.1% of revenue in FY2025, up 68.6 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -6.7% toward the trailing-twelve-month pace of -0.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.74M+8.9% QoQ
Last fiscal yearDec 2025
$19.61M+9.5% YoY
LTMMar 2026
$19.27M-0.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.7%——
1 year+9.5%——
3-year CAGR+25.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
19.61M USD
Year-over-year change
+9.5%
4-year CAGR
+66.9%

Stock-Based Compensation vs competitors

How TRDA compares with its peers on the latest reported figures

  • TRDA's LTM Mar 2026 stock-based compensation of $19.27M is the 4th largest of the 11 companies compared; the peer median is $12.02M.
  • Its year-over-year change of -0.0% is the 4th highest of 11, against a peer median of -16.0%.
  • Stock-based compensation amounts to 335.8% of revenue for TRDA, versus a peer median of 44.1%.
TRDA Competitors Peer median
Stock-Based Compensation for TRDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$3.98B +32410.1%+56.9%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M -35.1%-23.4%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$23.07M -33.2%-6.0%50.9%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$19.27M -0.0%+25.6%335.8%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$17.5M -62.1%-23.7%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$13.6M -8.6%+16.5%37.3%
HUMAHumacyte, Inc.LTM Mar 2026$10.44M +45.6%+16.4%517.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$9.07M -23.3%-16.5%4.2%
SGMTSagimet Biosciences Inc.LTM Mar 2026$6.82M +13.6%+50.8%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$5.84M -6.8%+38.9%—
IMRXImmuneering CorporationLTM Mar 2026$1.52M -69.5%——
Peer median (excluding TRDA) $12.02M-16.0%+16.4%44.1%

Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Depreciation & Amortization1.12M1.9M2.84M3.77M4.1M
Deferred Income Tax00000
Stock-Based Compensation2.53M9.9M13.11M17.92M19.61M
Change in Working Capital(3.42M)(11.11M)136.32M(118.85M)(4.8M)
Accounts Receivables0002.2M2.5M
Inventory00000
Accounts Payables(715K)5.29M(2.81M)991K(1.8M)
Other Working Capital(2.71M)(16.4M)139.12M(122.04M)(5.5M)
Other Non-Cash Items74K151K(5.78M)(10.02M)(3.67M)
Operating Cash Flow(50.86M)(93.79M)139.8M(41.56M)(128.51M)
Capital Expenditures(4.58M)(2.89M)(5.61M)(3.16M)(1.04M)
Acquisitions (Net)00000
Purchases of Investments0(221.98M)(407.21M)(437.72M)(141.61M)
Sales of Investments076.21M274.43M413.08M259.46M
Other Investing Activities00000
Investing Cash Flow(4.58M)(148.65M)(138.4M)(27.8M)116.81M
Debt Repayment00000
Common Stock Issued190.69M479K19.41M99.61M887K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities939K01.63M3.36M0
Financing Cash Flow307.46M479K21.04M102.96M887K
Effect of Forex Changes0(3.95M)000
Net Change in Cash252.02M(245.91M)22.45M33.61M(10.82M)
Free Cash Flow(55.44M)(96.67M)134.19M(44.72M)(129.55M)

Entrada Therapeutics, Inc.

NASDAQ:TRDA

Intrinsic Alpha fair value

Locked

Current Price

$5.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.